- Trial phase
- No data found for ABCL385
- Time to market
- Not stated
- Why 1/10
- No hard, dated catalyst exists for ABCL385 because no public information about this drug candidate could be found. The drug does not appear in any clinical trial databases, SEC filings, press releases, or news coverage. ImpactScore defaults to 1 due to the lack of any identifiable program.
No information could be found on a drug called ABCL385. AbCellera's lead proprietary programs are ABCL635 (menopause/hot flashes, Phase 2 complete, Phase 3 planned for 2027) and ABCL575 (atopic dermatitis, Phase 1). The next major catalyst for ABCL is the Phase 3 initiation for ABCL635 expected in 2027, plus the UBS Global Biopharma Conference presentation on November 17, 2026.
Price Chart
Executive Summary
No public information could be found for a drug candidate called "ABCL385" from AbCellera Biologics (NASDAQ: ABCL). The name does not appear in any SEC filings, clinical trial registries, FDA databases, press releases, or news coverage. AbCellera's known proprietary pipeline consists of ABCL635 (Phase 2 completed for menopausal hot flashes, Phase 3 planned for 2027) and ABCL575 (Phase 1 for atopic dermatitis), along with partnered discovery programs. ABCL385 may be a very early preclinical program, a discontinued candidate, or a misidentification. The company trades at $11.95 with a market cap supported by its AI-driven antibody discovery platform and positive Phase 2 data for ABCL635.
How It Works
No information available. AbCellera is an antibody discovery and development company that uses an AI-powered platform to identify and engineer antibody drugs. Its known pipeline candidates include ABCL635 (targeting NK3R for menopausal hot flashes) and ABCL575 (targeting OX40L for atopic dermatitis).
Trial Status
No clinical trial data exists for ABCL385. AbCellera's lead proprietary program ABCL635 completed a Phase 2 trial for menopausal hot flashes with positive topline data announced August 10, 2026. ABCL575 is in Phase 1 for atopic dermatitis.
The Two-Sided Case
Upcoming Catalysts
- UBS Global Biopharma Conference presentation on November 17, 2026
- Phase 3 initiation for ABCL635 expected in 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbCellera Biologics Inc. 8-K ABCL ·Originating report